Metabolic engineering of antibiotic factories: New tools for antibiotic production in actinomycetes

Trends in Biotechnology

Volumn 33, Issue 1, 2015, Pages 15-26

  Weber, Tilmann ^a   Charusanti, Pep ^a,b   Musiol Kroll, Ewa Maria ^a   Jiang, Xinglin ^a   Tong, Yaojun ^a   Kim, Hyun Uk ^a,c   Lee, Sang Yup ^a,c  

^a Chalmers University of Technology   (Denmark)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Actinomycetes; Antibiotics; Metabolic engineering; Secondary metabolites

Indexed keywords

ANTIBIOTICS; BACTERIA; GENES; METABOLISM; METABOLITES;

ACTINOMYCETES; ANTIBIOTIC PRODUCTION; BIOACTIVE COMPOUNDS; BIOSYNTHETIC GENE CLUSTER; GENOME SEQUENCING; METABOLIC ENGINEERING APPROACH; MODIFIED PRODUCTS; SECONDARY METABOLITES;

METABOLIC ENGINEERING;

ANTIBIOTIC AGENT; AVERMECTIN; BLEOMYCIN; DNA; DOXORUBICIN; ERYTHROMYCIN; NYSTATIN; RAPAMYCIN; STREPTOMYCIN; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACTINOBACTERIA; ANTIBIOTIC BIOSYNTHESIS; BACTERIAL GENOME; DNA SYNTHESIS; DRUG INDUSTRY; DRUG MANUFACTURE; ESCHERICHIA COLI; GENE CLUSTER; GENE SEQUENCE; GENETIC ENGINEERING; HETEROLOGOUS EXPRESSION; METABOLIC ENGINEERING; METABOLITE; NONHUMAN; REVIEW; SACCHAROMYCES CEREVISIAE; BIOSYNTHESIS; DATA MINING; GENE EXPRESSION REGULATION; METABOLISM; MULTIGENE FAMILY; PROCEDURES;

ACTINOBACTERIA (CLASS);

ACTINOBACTERIA; ANTI-BACTERIAL AGENTS; DATA MINING; GENE EXPRESSION REGULATION, BACTERIAL; GENOME, BACTERIAL; METABOLIC ENGINEERING; MULTIGENE FAMILY;

EID: 84918813440     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.10.009     Document Type: Review

References (111)

1. Bérdy J. Thoughts and facts about antibiotics: where we are now and where we are heading. J. Antibiot. (Tokyo) 2012, 65:385-395.
2. Bachmann B.O., et al. Microbial genome mining for accelerated natural products discovery: is a renaissance in the making?. J. Ind. Microbiol. Biotechnol. 2014, 41:175-184.
3. Lee S.Y., et al. Metabolic engineering of microorganisms: general strategies and drug production. Drug Discov. Today 2009, 14:78-88.
4. Hwang K.S., et al. Systems biology and biotechnology of Streptomyces species for the production of secondary metabolites. Biotechnol. Adv. 2014, 32:255-268.
5. Weber T. In silico tools for the analysis of antibiotic biosynthetic pathways. Int. J. Med. Microbiol. 2014, 304:230-235.
6. Blin K., et al. antiSMASH 2.0 - a versatile platform for genome mining of secondary metabolite producers. Nucleic Acids Res. 2013, 41:W204-W212.
7. Helfrich E.J., et al. Recent advances in genome-based polyketide discovery. Curr. Opin. Biotechnol. 2014, 29C:107-115.
8. Krug D., Müller R. Secondary metabolomics: the impact of mass spectrometry-based approaches on the discovery and characterization of microbial natural products. Nat. Prod. Rep. 2014, 31:768-783.
9. Fischbach M.A., Walsh C.T. Assembly-line enzymology for polyketide and nonribosomal peptide antibiotics: logic, machinery, and mechanisms. Chem. Rev. 2006, 106:3468-3496.
10. Hertweck C. The biosynthetic logic of polyketide diversity. Angew. Chem. Int. Ed. Engl. 2009, 48:4688-4716.
11. Kersten R.D., et al. A mass spectrometry-guided genome mining approach for natural product peptidogenomics. Nat. Chem. Biol. 2011, 7:794-802.
12. Kersten R.D., et al. Glycogenomics as a mass spectrometry-guided genome-mining method for microbial glycosylated molecules. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E4407-E4416.
13. Chen Y., et al. A proteomic survey of nonribosomal peptide and polyketide biosynthesis in actinobacteria. J. Proteome Res. 2012, 11:85-94.
14. Gubbens J., et al. Natural product proteomining, a quantitative proteomics platform, allows rapid discovery of biosynthetic gene clusters for different classes of natural products. Chem. Biol. 2014, 21:707-718.
15. Ochi K., Hosaka T. New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters. Appl. Microbiol. Biotechnol. 2013, 97:87-98.
16. Charusanti P., et al. Exploiting adaptive laboratory evolution of Streptomyces clavuligerus for antibiotic discovery and overproduction. PLoS ONE 2012, 7:e33727.
17. Spohn M., et al. Overproduction of ristomycin A by activation of a silent gene cluster in Amycolatopsis japonicum MG417-CF17. Antimicrob. Agents Chemother. 2014, 58:6185-6196.
18. Olano C., et al. Activation and identification of five clusters for secondary metabolites in Streptomyces albus J1074. Microb. Biotechnol. 2014, 7:242-256.
19. Weber T., et al. Exploiting the genetic potential of polyketide producing streptomycetes. J. Biotechnol. 2003, 106:221-232.
20. Barkei J.J., et al. Investigations into viomycin biosynthesis by using heterologous production in Streptomyces lividans. Chembiochem 2009, 10:366-376.
21. Kim J.H., et al. Cloning large natural product gene clusters from the environment: piecing environmental DNA gene clusters back together with TAR. Biopolymers 2010, 93:833-844.
22. Kouprina N., Larionov V. Selective isolation of genomic loci from complex genomes by transformation-associated recombination cloning in the yeast Saccharomyces cerevisiae. Nat. Protoc. 2008, 3:371-377.
23. Fu J., et al. Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting. Nat. Biotechnol. 2012, 30:440-446.
24. Yamanaka K., et al. Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster yields the antibiotic taromycin A. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:1957-1962.
25. Gust B., et al. Lambda red-mediated genetic manipulation of antibiotic-producing Streptomyces. Adv. Appl. Microbiol. 2004, 54:107-128.
26. Binz T.M., et al. Heterologous expression and genetic engineering of the phenalinolactone biosynthetic gene cluster by using Red/ET recombineering. Chembiochem 2008, 9:447-454.
27. Gibson D.G., et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 2009, 6:343-345.
28. Li M.Z., Elledge S.J. Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat. Methods 2007, 4:251-256.
29. Shao Z., et al. DNA assembler, an in vivo genetic method for rapid construction of biochemical pathways. Nucleic Acids Res. 2009, 37:e16.
30. Geu-Flores F., et al. USER fusion: a rapid and efficient method for simultaneous fusion and cloning of multiple PCR products. Nucleic Acids Res. 2007, 35:e55.
31. Kok S.D., et al. Rapid and reliable DNA assembly via ligase cycling reaction. ACS Synth. Biol. 2014, 3:97-106.
32. Jiang X., et al. In vitro assembly of multiple DNA fragments using successive hybridization. PLoS ONE 2012, 7:e30267.
33. Chao R., et al. Recent advances in DNA assembly technologies. FEMS Yeast Res. 2014, Published online June 23, 2014. 10.1111/1567-1364.12171.
34. Zakeri B., Lu T.K. Synthetic biology of antimicrobial discovery. ACS Synth. Biol. 2012, 2:358-372.
35. Gomez-Escribano J.P., Bibb M.J. Streptomyces coelicolor as an expression host for heterologous gene clusters. Methods Enzymol. 2012, 517:279-300.
36. Komatsu M., et al. Engineered Streptomyces avermitilis host for heterologous expression of biosynthetic gene cluster for secondary metabolites. ACS Synth. Biol. 2013, 2:384-396.
37. Chen C.W., et al. Once the circle has been broken: dynamics and evolution of Streptomyces chromosomes. Trends Genet. 2002, 18:522-529.
38. Gomez-Escribano J.P., Bibb M.J. Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters. Microb. Biotechnol. 2011, 4:207-215.
39. Zhou M., et al. Sequential deletion of all the polyketide synthase and nonribosomal peptide synthetase biosynthetic gene clusters and a 900-kb subtelomeric sequence of the linear chromosome of Streptomyces coelicolor. FEMS Microbiol. Lett. 2012, 333:169-179.
40. Ikeda H., et al. Genome mining of the Streptomyces avermitilis genome and development of genome-minimized hosts for heterologous expression of biosynthetic gene clusters. J. Ind. Microbiol. Biotechnol. 2014, 41:233-250.
41. Komatsu M., et al. Genome-minimized Streptomyces host for the heterologous expression of secondary metabolism. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2646-2651.
42. Gaj T., et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013, 31:397-405.
43. Ryu Y.G., et al. Engineering of primary carbohydrate metabolism for increased production of actinorhodin in Streptomyces coelicolor. Appl. Environ. Microbiol. 2006, 72:7132-7139.
44. Thykaer J., et al. Increased glycopeptide production after overexpression of shikimate pathway genes being part of the balhimycin biosynthetic gene cluster. Metab. Eng. 2010, 12:455-461.
45. Mo S., et al. Application of a combined approach involving classical random mutagenesis and metabolic engineering to enhance FK506 production in Streptomyces sp. RM7011. Appl. Microbiol. Biotechnol. 2013, 97:3053-3062.
46. Williams G.J. Engineering polyketide synthases and nonribosomal peptide synthetases. Curr. Opin. Struct. Biol. 2013, 23:603-612.
47. McDaniel R., et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel 'unnatural' natural products. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1846-1851.
48. Thirlway J., et al. Introduction of a non-natural amino acid into a nonribosomal peptide antibiotic by modification of adenylation domain specificity. Angew. Chem. Int. Ed. Engl. 2012, 51:7181-7184.
49. Sugimoto Y., et al. Rational design of modular polyketide synthases: morphing the aureothin pathway into a luteoreticulin assembly line. Angew. Chem. Int. Ed. Engl. 2014, 53:1560-1564.
50. Thaker M.N., Wright G.D. Opportunities for synthetic biology in antibiotics: expanding glycopeptide chemical diversity. ACS Synth. Biol. 2012, Published online December 17, 2012. 10.1021/sb300092n.
51. Gaisser S., et al. A defined system for hybrid macrolide biosynthesis in Saccharopolyspora erythraea. Mol. Microbiol. 2000, 36:391-401.
52. Fu X., et al. Antibiotic optimization via in vitro glycorandomization. Nat. Biotechnol. 2003, 21:1467-1469.
53. Han A.R., et al. Development of a Streptomyces venezuelae-based combinatorial biosynthetic system for the production of glycosylated derivatives of doxorubicin and its biosynthetic intermediates. Appl. Environ. Microbiol. 2011, 77:4912-4923.
54. Qiu Y., et al. Structural and operational complexity of the Geobacter sulfurreducens genome. Genome Res. 2010, 20:1304-1311.
55. Cho B.K., et al. The transcription unit architecture of the Escherichia coli genome. Nat. Biotechnol. 2009, 27:1043-1049.
56. Whicher J.R., et al. Structural rearrangements of a polyketide synthase module during its catalytic cycle. Nature 2014, 510:560-564.
57. Dutta S., et al. Structure of a modular polyketide synthase. Nature 2014, 510:512-517.
58. Bloudoff K., et al. Crystal structures of the first condensation domain of CDA synthetase suggest conformational changes during the synthetic cycle of nonribosomal peptide synthetases. J. Mol. Biol. 2013, 425:3137-3150.
59. Yadav G., et al. Prediction of inter domain interactions in modular polyketide synthases by docking and correlated mutation analysis. J. Biomol. Struct. Dyn. 2013, 31:17-29.
60. Wright G. Perspective: synthetic biology revives antibiotics. Nature 2014, 509:S13.
61. Medema M.H., et al. Exploiting plug-and-play synthetic biology for drug discovery and production in microorganisms. Nat. Rev. Microbiol. 2011, 9:131-137.
62. Miao V., et al. Daptomycin biosynthesis in Streptomyces roseosporus: cloning and analysis of the gene cluster and revision of peptide stereochemistry. Microbiology 2005, 151:1507-1523.
63. Bian X., et al. Direct cloning, genetic engineering, and heterologous expression of the syringolin biosynthetic gene cluster in E. coli through Red/ET recombineering. Chembiochem 2012, 13:1946-1952.
64. Pfeifer B.A., et al. Biosynthesis of complex polyketides in a metabolically engineered strain of E. coli. Science 2001, 291:1790-1792.
65. Zhang H.R., et al. Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem. Biol. 2010, 17:1232-1240.
66. Chen W-H., et al. The MASTER (methylation-assisted tailorable ends rational) ligation method for seamless DNA assembly. Nucleic Acids Res. 2013, 41:e93.
67. Shao Z., et al. Refactoring the silent spectinabilin gene cluster using a plug-and-play scaffold. ACS Synth. Biol. 2013, 2:662-669.
68. Zhang L., et al. Tandem assembly of the epothilone biosynthetic gene cluster by in vitro site-specific recombination. Sci. Rep. 2011, 1:141.
69. Schimming O., et al. Yeast homologous recombination cloning leading to the novel peptides ambactin and xenolindicin. Chembiochem 2014, 15:1290-1294.
70. Malla S., et al. Improvement in doxorubicin productivity by overexpression of regulatory genes in Streptomyces peucetius. Res. Microbiol. 2010, 161:109-117.
71. Butler M.J., et al. Deletion of scbA enhances antibiotic production in Streptomyces lividans. Appl. Microbiol. Biotechnol. 2003, 61:512-516.
72. Olano C., et al. Improving production of bioactive secondary metabolites in actinomycetes by metabolic engineering. Metab. Eng. 2008, 10:281-292.
73. Huang D., et al. Enhancement of FK506 production by engineering secondary pathways of Streptomyces tsukubaensis and exogenous feeding strategies. J. Ind. Microbiol. Biotechnol. 2013, 40:1023-1037.
74. Mo S., et al. Enhanced FK506 production in Streptomyces clavuligerus CKD1119 by engineering the supply of methylmalonyl-CoA precursor. J. Ind. Microbiol. Biotechnol. 2009, 36:1473-1482.
75. Reeves A.R., et al. Engineering of the methylmalonyl-CoA metabolite node of Saccharopolyspora erythraea for increased erythromycin production. Metab. Eng. 2007, 9:293-303.
76. Chen Y., et al. Genetic modulation of the overexpression of tailoring genes eryK and eryG leading to the improvement of erythromycin A purity and production in Saccharopolyspora erythraea fermentation. Appl. Environ. Microbiol. 2008, 74:1820-1828.
77. Wang G., et al. Dramatic activation of antibiotic production in Streptomyces coelicolor by cumulative drug resistance mutations. Appl. Environ. Microbiol. 2008, 74:2834-2840.
78. Malla S., et al. Self-resistance mechanism in Streptomyces peucetius: overexpression of drrA, drrB and drrC for doxorubicin enhancement. Microbiol. Res. 2010, 165:259-267.
79. Qiu J., et al. Overexpression of the ABC transporter AvtAB increases avermectin production in Streptomyces avermitilis. Appl. Microbiol. Biotechnol. 2011, 92:337-345.
80. Oliynyk M., et al. A hybrid modular polyketide synthase obtained by domain swapping. Chem. Biol. 1996, 3:833-839.
81. Patel K., et al. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem. Biol. 2004, 11:1625-1633.
82. Gaisser S., et al. Direct production of ivermectin-like drugs after domain exchange in the avermectin polyketide synthase of Streptomyces avermitilis ATCC31272. Org. Biomol. Chem. 2003, 1:2840-2847.
83. Hopwood D.A., et al. Production of 'hybrid' antibiotics by genetic engineering. Nature 1985, 314:642-644.
84. Omura S., et al. Production of new hybrid antibiotics, mederrhodins A and B, by a genetically engineered strain. Antimicrob. Agents Chemother. 1986, 29:13-19.
85. Reeves C.D., et al. Production of hybrid 16-membered macrolides by expressing combinations of polyketide synthase genes in engineered Streptomyces fradiae hosts. Chem. Biol. 2004, 11:1465-1472.
86. Mo S., et al. Production of branched-chain alkylprodiginines in S. coelicolor by replacement of the 3-ketoacyl ACP synthase III initiation enzyme, RedP. Chem. Biol. 2005, 12:191-200.
87. Ito T., et al. Deciphering pactamycin biosynthesis and engineered production of new pactamycin analogues. Chembiochem 2009, 10:2253-2265.
88. Power P., et al. Engineered synthesis of 7-oxo- and 15-deoxy-15-oxo-amphotericins: insights into structure-activity relationships in polyene antibiotics. Chem. Biol. 2008, 15:78-86.
89. Schwarzer D., et al. Exploring the impact of different thioesterase domains for the design of hybrid peptide synthetases. Chem. Biol. 2001, 8:997-1010.
90. Tang Y., et al. Engineered biosynthesis of regioselectively modified aromatic polyketides using bimodular polyketide synthases. PLoS Biol. 2004, 2:E31.
91. Nguyen K.T., et al. Combinatorial biosynthesis of novel antibiotics related to daptomycin. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17462-17467.
92. Yu G., et al. Genome shuffling of Streptomyces roseosporus for improving daptomycin production. Appl. Biochem. Biotechnol. 2014, 172:2661-2669.
93. Doekel S., et al. Non-ribosomal peptide synthetase module fusions to produce derivatives of daptomycin in Streptomyces roseosporus. Microbiology 2008, 154:2872-2880.
94. Gomez C., et al. Novel compounds produced by Streptomyces lydicus NRRL 2433 engineered mutants altered in the biosynthesis of streptolydigin. J. Antibiot. (Tokyo) 2012, 65:341-348.
95. Evans B.S., et al. Directed evolution of the nonribosomal peptide synthetase AdmK generates new andrimid derivatives in vivo. Chem. Biol. 2011, 18:601-607.
96. Malla S., et al. Enhancement of doxorubicin production by expression of structural sugar biosynthesis and glycosyltransferase genes in Streptomyces peucetius. J. Biosci. Bioeng. 2009, 108:92-98.
97. Sanchez C., et al. Combinatorial biosynthesis of antitumor indolocarbazole compounds. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:461-466.
98. Heide L. Genetic engineering of antibiotic biosynthesis for the generation of new aminocoumarins. Biotechnol. Adv. 2009, 27:1006-1014.
99. Mendez C., Salas J.A. Altering the glycosylation pattern of bioactive compounds. Trends Biotechnol. 2001, 19:449-456.
100. Luzhetskyy A., et al. Glycosyltransferases, important tools for drug design. Curr. Top. Med. Chem. 2008, 8:680-709.
101. Shinde P.B., et al. Combinatorial biosynthesis and antibacterial evaluation of glycosylated derivatives of 12-membered macrolide antibiotic YC-17. J. Biotechnol. 2013, 168:142-148.
102. Zhu T., et al. Deciphering and engineering of the final step halogenase for improved chlortetracycline biosynthesis in industrial Streptomyces aureofaciens. Metab. Eng. 2013, 19:69-78.
103. Mendes M.V., et al. Engineered biosynthesis of novel polyenes: a pimaricin derivative produced by targeted gene disruption in Streptomyces natalensis. Chem. Biol. 2001, 8:635-644.
104. Remsing L.L., et al. Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis. J. Am. Chem. Soc. 2003, 125:5745-5753.
105. Ju J., et al. Functional characterization of ttmM unveils new tautomycin analogs and insight into tautomycin biosynthesis and activity. Org. Lett. 2009, 11:1639-1642.
106. Zhang M.Q., et al. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. J. Med. Chem. 2008, 51:5494-5497.
107. Khaw L.E., et al. Mutational biosynthesis of novel rapamycins by a strain of Streptomyces hygroscopicus NRRL 5491 disrupted in rapL, encoding a putative lysine cyclodeaminase. J. Bacteriol. 1998, 180:809-814.
108. Weist S., et al. Fluorobalhimycin - a new chapter in glycopeptide antibiotic research. Angew. Chem. Int. Ed. Engl. 2002, 41:3383-3385.
109. Galm U., et al. In vitro and in vivo production of new aminocoumarins by a combined biochemical, genetic, and synthetic approach. Chem. Biol. 2004, 11:173-183.
110. Kim W., et al. Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. Chembiochem 2007, 8:1491-1494.
111. Lechner A., et al. Designed biosynthesis of 36-methyl-FK506 by polyketide precursor pathway engineering. ACS Synth. Biol. 2013, 2:379-383.